Lipidation-dimerization platform unlocks treatment potential of fibroblast growth factor 21 for non-alcoholic steatohepatitis.
Wang Y, Shen L, Wang C, Dong Y, Hua H, Xu J, Zhang Y, Huang H, Huang Z, Zhao F, Xu Z, Qiu Y, Lu J, Ju D, Feng J.
Wang Y, et al. Among authors: xu j, xu z.
J Control Release. 2024 Nov 9;376:1130-1142. doi: 10.1016/j.jconrel.2024.11.006. Online ahead of print.
J Control Release. 2024.
PMID: 39510256